diff --git a/capture-signal-cgm-assets.sh b/capture-signal-cgm-assets.sh deleted file mode 100755 index d5ac8f8..0000000 --- a/capture-signal-cgm-assets.sh +++ /dev/null @@ -1,1165 +0,0 @@ -#!/usr/bin/env bash -# ============================================================================= -# capture-signal-cgm-assets.sh -# Captures Signal CGM strategic analysis outputs, commits to Git, syncs Obsidian -# Idempotent — safe to run multiple times -# ============================================================================= -set -euo pipefail - -# ── Configuration ───────────────────────────────────────────────────────────── -SCRIPT_DIR="$(cd "$(dirname "${BASH_SOURCE[0]}")" && pwd)" -REPO_ROOT="$SCRIPT_DIR" -OUTPUT_DIR="$REPO_ROOT/CGM-Denial-Prevention/01-Claude-Outputs" -ANALYSIS_DIR="$OUTPUT_DIR/Analysis" -ASSETS_DIR="$OUTPUT_DIR/Assets" -OBSIDIAN_DIR="/Users/sttil-solutions/Documents/Obsidian_Vault/STTIL-Vault/Projects/DMEPOS/CGM-Analysis" - -# ── Helpers ─────────────────────────────────────────────────────────────────── -log() { echo " → $*"; } -ok() { echo " ✓ $*"; } -fail() { echo " ✗ $*" >&2; exit 1; } - -echo "" -echo "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━" -echo " Signal CGM — Asset Capture Script" -echo "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━" - -# ── Step 1: Directory Structure ─────────────────────────────────────────────── -log "Creating directory structure..." -mkdir -p "$ANALYSIS_DIR" "$ASSETS_DIR" -ok "Directories ready" - -# ============================================================================= -# FILE 61 — signal-cgm-segment-scoring-v1.md -# Source: "Re-rank the customer segments using an explicit scoring model" -# ============================================================================= -log "Writing signal-cgm-segment-scoring-v1.md..." -cat > "$ANALYSIS_DIR/signal-cgm-segment-scoring-v1.md" << 'ENDDOC' -# Signal CGM — Segment Scoring Model v1 -### Explicit Criteria, Weights, and Rankings Across Three Objectives -### STTIL Solutions LLC | April 2026 - ---- - -## Scoring Architecture - -Three independent rankings. Each uses different criteria, weights, and success -definitions. A segment that ranks #1 for SaaS ICP may be wrong for a pilot and -irrelevant for an asset sale. Treat them as separate decisions. - ---- - -## Model 1: Best SaaS ICP for MRR/ARR - -| Criterion | Weight | What it measures | -|-----------|--------|-----------------| -| Pain intensity | 25% | How acutely the segment feels the CGM denial problem | -| Willingness / ability to pay | 20% | Named budget, ROI clarity, buyer who can sign | -| Revenue per customer (ARR × LTV) | 20% | Monthly contract × expected contract duration | -| Sales cycle speed | 15% | Weeks from first contact to signed contract | -| Churn durability | 10% | Still exists and values the tool in 24 months? | -| Reachability at scale | 10% | Find and reach efficiently without large sales org | - -### SaaS ICP Scores - -| Segment | Pain (25%) | Pay (20%) | ARR×LTV (20%) | Cycle (15%) | Churn (10%) | Reach (10%) | Score | -|---------|-----------|-----------|--------------|-------------|------------|-------------|-------| -| Mid-size supplier (10–50 emp) | 9 | 8 | 8 | 7 | 6 | 7 | **7.80** | -| Billing company / DME RCM | 8 | 7 | 7 | 5 | 8 | 6 | **6.95** | -| Small supplier (2–8 emp) | 10 | 5 | 4 | 6 | 4 | 8 | **6.40** | -| VGM Group / MSO | 5 | 4 | 7 | 3 | 9 | 5 | **5.30** | -| DME platform vendor (NikoHealth) | 3 | 4 | 8 | 2 | 9 | 3 | **4.65** | -| State / national association | 2 | 1 | 1 | 3 | 7 | 9 | **2.55** | -| Grant-funded / QI org | 3 | 2 | 2 | 2 | 4 | 4 | **2.60** | - -**Key rationale:** -- Mid-size supplier leads because they have pain + budget + ROI clarity at $199–$399/month -- Small supplier has maximum pain (10/10) but minimum reliability — high churn risk as CB 2028 approaches -- Billing company scores #2: absorbs denial labor directly; LTV longer than any individual supplier -- NikoHealth scores low on SaaS — they are an asset buyer, not a subscriber - ---- - -## Model 2: Best Buyer for Asset Sale / Strategic Handoff - -| Criterion | Weight | What it measures | -|-----------|--------|-----------------| -| Distribution reach | 30% | How many suppliers does this buyer already reach? | -| Strategic need | 25% | Documented feature gap; would they build it otherwise? | -| Price ceiling | 20% | How much would a motivated buyer plausibly pay? | -| Speed to close | 15% | Weeks from conversation to signed term sheet | -| Build vs. buy calculus | 10% | Is acquiring faster than building given CB 2028 window? | - -### Asset Sale Scores - -| Segment | Distribution (30%) | Need (25%) | Price (20%) | Speed (15%) | B/B (10%) | Score | -|---------|-------------------|-----------|------------|-------------|-----------|-------| -| DME platform vendor (NikoHealth) | 10 | 9 | 9 | 3 | 7 | **8.20** | -| VGM Group / MSO | 10 | 7 | 7 | 4 | 8 | **7.55** | -| Billing company / DME RCM | 7 | 8 | 6 | 5 | 7 | **6.75** | -| State / national association | 8 | 4 | 2 | 2 | 3 | **4.40** | -| Mid-size supplier | 1 | 5 | 2 | 4 | 3 | **2.85** | -| Small supplier | 1 | 4 | 1 | 3 | 2 | **2.10** | -| Grant-funded / QI org | 3 | 3 | 2 | 1 | 2 | **2.40** | - -**NikoHealth (#1 asset buyer) rationale:** -- Already serves the exact buyer profile; CGM feature gap is documented and real -- API-first architecture makes integration technically trivial -- CB 2028 window makes buying faster than 6–9 month internal build -- Price ceiling is 3–5× current $25K–$60K ask for a motivated platform buyer - ---- - -## Model 3: Best Pilot Validation Partner - -| Criterion | Weight | What it measures | -|-----------|--------|-----------------| -| Data accessibility | 25% | Structured CGM billing data with denial reason codes | -| Cooperation likelihood | 20% | Will they actively participate and give feedback? | -| Signal quality | 20% | Will pilot results generalize to target market? | -| PHI / compliance overhead | 20% | BAA and data security burden | -| Feedback loop speed | 15% | How quickly is denial rate change measurable? | - -### Pilot Scores - -| Segment | Data (25%) | Coop (20%) | Signal (20%) | PHI (20%) | Speed (15%) | Score | -|---------|-----------|-----------|-------------|----------|------------|-------| -| Billing company / DME RCM | 10 | 7 | 10 | 6 | 6 | **8.00** | -| Mid-size supplier | 8 | 8 | 9 | 5 | 8 | **7.60** | -| DME platform vendor | 10 | 4 | 10 | 7 | 4 | **7.30** | -| Small supplier | 6 | 9 | 7 | 5 | 7 | **6.75** | -| VGM / MSO | 3 | 5 | 4 | 4 | 3 | **3.80** | - -**Billing company leads pilot scoring** because they have multi-supplier, -multi-plan, multi-jurisdiction billing data — the fastest path to H1 validation -(denials are documentation-fixable) across a meaningful sample size. - ---- - -## Government Enforcement Context - -| Finding | Source | Strategic Implication | -|---------|--------|----------------------| -| CGM improper payment rate: 25.2% / $278.5M/yr | CMS 2024 | One in four CGM dollars improperly paid | -| 94.2% from documentation failures | CMS 2024 | Not fraud — fixable workflow gaps | -| $1.9B total DMEPOS improper payments FY2024 | OIG | CGM is highest-scrutiny category | -| $1.8B in payments suspended 2025 | CMS Fraud Defense Ops | Enforcement is executing at scale now | -| CGM as explicit 2026 enforcement priority | OIG / DOJ | Legitimate suppliers get caught in sweeps | -| Unequal enforcement: pharmacy vs DMEPOS | CMS-2025-0242-0025 | DMEPOS held to higher standard than pharmacy for same product | - -**The dual-edge positioning:** Signal CGM's audit log is not just a billing tool — -it is liability documentation. A supplier who can show time-stamped pre-submission -checks has a defensibility argument when the MAC issues an ADR. - ---- - -## NikoHealth Foothold Assessment - -**Verdict: Credible and growing challenger. Not the market standard.** - -| Indicator | Assessment | -|-----------|-----------| -| Architecture | Cloud-native, API-first — genuine advantage over Brightree | -| Pricing | More accessible for small suppliers than Brightree ($600–$1,500+/mo) | -| Market position | Capturing switchers from legacy platforms; not dominant | -| Customer count | G2 review volume suggests low hundreds, not thousands | -| CGM-specific intelligence | Generic authorization alerts; no 6-month visit tracking, no MAC-jurisdiction rules, no 45-day runway logic | -| Competitive risk | Could close the CGM gap in 6–9 months of focused engineering | - -**Asset sale timing window: open but not permanent.** NikoHealth's API-first -architecture makes acquisition or licensing integration technically trivial -relative to Brightree's legacy stack. - ---- - -## Sources -- [CMS 2024 CGM Improper Payment Data](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) -- [OIG 2025: CGM Payments Exceeded Supplier Costs](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) -- [KFF: MA Prior Authorization 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) -- [Unequal DME/Pharmacy Enforcement — CMS Comment Record](https://downloads.regulations.gov/CMS-2025-0242-0025/attachment_1.pdf) -- [NikoHealth G2 Reviews 2026](https://www.g2.com/products/nikohealth/reviews) -- [DME/HME Software 2026 — Coruzant](https://coruzant.com/software/dme-and-hme-software-in-2026/) -- [DOJ $14.6B Healthcare Fraud Takedown 2025](https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-324-defendants-charged-connection-over-146-billion) -- [Federal Authorities Targeting CGM Reimbursement — Nat'l Law Review](https://natlawreview.com/article/federal-authorities-are-targeting-continuous-glucose-monitoring-cgm-device) -ENDDOC -ok "signal-cgm-segment-scoring-v1.md written" - -# ============================================================================= -# FILE 62 — signal-cgm-re-scored-composite-v2.md -# Source: "Take the prior scoring model and re-run it with new priority order" -# ============================================================================= -log "Writing signal-cgm-re-scored-composite-v2.md..." -cat > "$ANALYSIS_DIR/signal-cgm-re-scored-composite-v2.md" << 'ENDDOC' -# Signal CGM — Re-Scored Composite Model v2 -### Asset Sale Primary (50%) · Pilot Secondary (30%) · SaaS Tertiary (20%) -### MA + Medicaid First Proof-of-Concept Payer Scope -### STTIL Solutions LLC | April 2026 - ---- - -## Priority Weights - -| Objective | Weight | Rationale | -|-----------|--------|-----------| -| Asset sale / strategic handoff | 50% | Fastest path to capital realization | -| Pilot validation | 30% | Evidence from pilot raises asset sale price | -| SaaS ICP potential | 20% | Informs asset buyer's deployment ROI | - ---- - -## Scoring Assumption Audit - -### Asset Sale — Why These Weights - -**Distribution reach (30%):** An asset sale to a platform touching 500+ suppliers -is worth orders of magnitude more than one touching one. This is the dominant -criterion because it determines the multiplier on the asset's downstream value. - -**Strategic need (25%):** Pull motion (buyer has documented gap) is more reliable -than push motion (we convince buyer they need it). NikoHealth's CGM intelligence -gap is documented and real. Billing companies' MA plan-rule complexity is felt daily. - -**Price ceiling (20%):** Current $25K–$60K is priced for a direct supplier buyer. -A platform vendor or MSO can justify 3–5× that. Weight at 20% because price ceiling -is contingent on strategic need — no need, no premium. - -**Speed to close (15%):** Closing faster is better but not at the expense of deal -size. Pursue fast-close candidates in parallel with long-cycle targets. - -**Build vs. buy (10%):** Modifier on other criteria. Accelerates a deal that -already has strategic need; doesn't create one where those are absent. - -### Pilot — Why These Weights - -**Data accessibility (25%):** Pilot must generate measurable denial rate change. -Requires structured CGM billing data with denial reason codes — not spreadsheets. - -**Cooperation likelihood (20%):** Active partner engagement multiplies data access -value. Poor data + high cooperation still generates useful qualitative signal. - -**Signal quality (20%):** Pilot must generalize to the asset buyer's customer base. -Single Florida supplier = anecdote. Billing company across 3 MACs = evidence. - -**PHI/compliance overhead (20%):** High-overhead pilot = delayed pilot. Given CB -2028 window, compliance friction is a real timeline risk. - -**Feedback loop speed (15%):** A 30–60 day feedback cycle is acceptable; -6 months is not viable given the urgency window. - ---- - -## Individual Segment Scores — MA + Medicaid Scope Applied - -### NikoHealth-Type Platform Vendor - -**Asset Sale Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Distribution reach | 30% | 10 | Serves exact buyer profile across hundreds of suppliers | -| Strategic need | 25% | 10 (+1) | MA+Medicaid scope widens the gap — no platform has plan-specific rules | -| Price ceiling | 20% | 9 | MA module = 3–5× current ask to a motivated platform buyer | -| Speed to close | 15% | 3 | Enterprise procurement: 4–8 months minimum | -| Build vs. buy | 10% | 8 (+1) | MA plan-rule maintenance is ongoing data work, not a sprint | -**Sub-score: 8.55** - -**Pilot Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Data accessibility | 25% | 10 | Best dataset: all supplier clients across all payers | -| Cooperation likelihood | 20% | 3 (−1) | Exposing own platform gap is sensitive under MA scope | -| Signal quality | 20% | 10 | Multi-supplier, multi-plan, multi-jurisdiction | -| PHI overhead | 20% | 7 | HIPAA infrastructure exists | -| Feedback speed | 15% | 4 | Enterprise review before data access | -**Sub-score: 7.10** - -**SaaS ICP Score: 4.65** -**NikoHealth Composite: (8.55×0.50) + (7.10×0.30) + (4.65×0.20) = 7.34** - ---- - -### Billing Company / DME RCM Outsourcer - -**Asset Sale Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Distribution reach | 30% | 7 | Serves 10–50 DMEPOS clients per firm | -| Strategic need | 25% | 9 (+1) | MA plan-specific PA rules are their most expensive unsolved problem | -| Price ceiling | 20% | 7 (+1) | $40K–$80K justified across 20+ clients under MA scope | -| Speed to close | 15% | 5 | Owner/managing partner: 60–90 day decision cycle | -| Build vs. buy | 10% | 7 | Not a tech company; will buy | -**Sub-score: 7.20** - -**Pilot Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Data accessibility | 25% | 10 | MA + Medicaid billing data across all clients — defines the advantage | -| Cooperation likelihood | 20% | 8 (+1) | MA complexity is their daily pain; highly motivated under this payer scope | -| Signal quality | 20% | 10 | Multi-supplier, multi-plan data | -| PHI overhead | 20% | 6 | HIPAA infrastructure exists; BAA manageable | -| Feedback speed | 15% | 6 | Fast initiation; first MA cycle data in 30 days | -**Sub-score: 8.20** - -**SaaS ICP Score: 7.75 (+0.80 under MA scope — tool becomes a revenue line)** -**Billing Company Composite: (7.20×0.50) + (8.20×0.30) + (7.75×0.20) = 7.61** - ---- - -### VGM Group / MSO - -**Asset Sale Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Distribution reach | 30% | 10 | Thousands of small-to-mid DMEPOS suppliers nationally | -| Strategic need | 25% | 6 (−1) | MA/Medicaid are plan-specific problems outside VGM's policy leverage | -| Price ceiling | 20% | 7 | $75K–$150K justified as member benefit | -| Speed to close | 15% | 3 | 6–12 month committee procurement | -| Build vs. buy | 10% | 8 | VGM endorses/buys tools, does not build | -**Sub-score: 7.15** - -**Pilot Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Data accessibility | 25% | 3 | No supplier billing data; must recruit members | -| Cooperation likelihood | 20% | 5 | Conceptual support; cannot drive participation | -| Signal quality | 20% | 3 (−1) | Member base skews rural/small; less MA density | -| PHI overhead | 20% | 4 | VGM as intermediary adds complexity layer | -| Feedback speed | 15% | 3 | Slow: member recruitment + separate BAAs | -**Sub-score: 3.60** - -**SaaS ICP Score: 5.30** -**VGM Composite: (7.15×0.50) + (3.60×0.30) + (5.30×0.20) = 5.72** - ---- - -### Mid-Size Independent Supplier - -**Asset Sale Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Distribution reach | 30% | 1 | Single supplier; no scale | -| Strategic need | 25% | 6 (+1) | MA scope raises personal pain — daily multi-plan complexity | -| Price ceiling | 20% | 3 (+1) | MA ROI strengthens argument; still marginal for asset sale | -| Speed to close | 15% | 4 | Owner decision: 2–8 weeks if motivated | -| Build vs. buy | 10% | 3 | Cannot build; would subscribe not buy | -**Sub-score: 3.30** - -**Pilot Sub-Score:** -| Criterion | Wt | Score | Note | -|-----------|-----|-------|------| -| Data accessibility | 25% | 7 | Structured in Brightree/NikoHealth; needs 50+ MA patients for signal | -| Cooperation likelihood | 20% | 8 | Billing manager engages daily; highly motivated | -| Signal quality | 20% | 7 (−2) | Thin MA mix reduces cross-plan generalizability | -| PHI overhead | 20% | 5 | BAA: standard, manageable | -| Feedback speed | 15% | 8 | Monthly MA billing cycle; fast iteration | -**Sub-score: 6.95** - -**SaaS ICP Score: 8.10 (+0.30 — MA complexity is their most expensive unsolved problem)** -**Mid-Size Supplier Composite: (3.30×0.50) + (6.95×0.30) + (8.10×0.20) = 5.36** - ---- - -## Composite Ranking Summary (Base + MA/Medicaid Adjusted) - -| Rank | Segment | Base Composite | MA+Med Adj | Final Score | -|------|---------|---------------|-----------|-------------| -| #1 | Billing company / DME RCM | 7.17 | +0.44 | **7.61** | -| #2 | NikoHealth-type platform | 7.22 | +0.12 | **7.34** | -| #3 | VGM Group / MSO | 5.98 | −0.26 | **5.72** | -| #4 | Mid-size independent supplier | 5.27 | +0.09 | **5.36** | - ---- - -## The Sequencing Logic - -The #1 and #2 positions are 0.27 points apart. This is not a clear winner — -it is a parallel tracks signal: - -1. **Pilot with billing company first.** 60 days. Generates denial rate - reduction data from real MA + Medicaid billing. Low cost. - -2. **Use that evidence to close NikoHealth.** The pilot data makes the - NikoHealth asset sale conversation 3× easier and likely 2× more valuable - in price negotiation. - -These tracks are mutually reinforcing, not competing. - -**VGM is the correct follow-on distribution deal** after the NikoHealth asset -sale or billing company deployment — not the primary target during MA + Medicaid -proof-of-concept. - ---- - -## MA + Medicaid: The Payer Complexity That Changes Everything - -``` -FFS Medicare: One ruleset per MAC jurisdiction (4 MACs nationally) -Medicare Advantage: 800+ plans, each with plan-specific PA rules - layered on top of CMS Part B baseline -Medicaid: 50 state rulesets, often MCO-layered within each state - TRAP: Several states have moved CGM coverage to pharmacy-only - (NY May 2024; others following) — verify before piloting -``` - -**Why this matters for NikoHealth:** Maintaining current MA plan-specific -PA rules across 800+ plans is ongoing data work, not engineering. A supplier -tool that owns this database has a moat that is expensive to replicate. - -**Why this matters for billing companies:** They are already maintaining -these rules manually in someone's spreadsheet. The pain is personal and daily. - ---- - -## Key Denial Quantification - -| Metric | Value | Source | -|--------|-------|--------| -| CGM improper payment rate | 25.2% | CMS 2024 | -| Projected annual improper payments | $278.5M | CMS 2024 | -| Documentation failure share | 94.2% | CMS 2024 | -| No documentation at all | 67.6% | CMS 2024 | -| Insufficient documentation | 26.6% | CMS 2024 | -| MA DMEPOS appeal success (L2) | 63.9% | KFF 2024 | -| MA PA denial rate | 7.7% | KFF 2024 | -| Write-off rate on denied claims | ~63% | Derived from appeal ladder economics | -| Net revenue loss after appeals | ~20% of gross CGM billing | Derived | - ---- - -## Sources -- [CMS 2024 CGM Improper Payments](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) -- [KFF: MA 53M PA Determinations 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) -- [MA Denial Spike — Medicare Rights Center](https://www.medicarerights.org/medicare-watch/2024/09/26/medicare-advantage-denials-increased-before-the-implementation-of-new-prior-authorization-rules) -- [Unequal DME/Pharmacy Enforcement — CMS Comment](https://downloads.regulations.gov/CMS-2025-0242-0025/attachment_1.pdf) -- [UHC/Synapse Health State Expansion](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) -- [OIG CGM Payments Exceeded Costs 2025](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) -- [NY State Medicaid CGM Billing Update 2024](https://www.emedny.org/ProviderManuals/communications/billing_glucose_monitors_-_5-9-24.pdf) -- [NikoHealth vs Brightree 2026](https://coruzant.com/software/dme-and-hme-software-in-2026/) -ENDDOC -ok "signal-cgm-re-scored-composite-v2.md written" - -# ============================================================================= -# FILE 63 — signal-cgm-final-ranking-leverage-v3.md -# Source: "Using the latest composite scoring model..." final analysis -# ============================================================================= -log "Writing signal-cgm-final-ranking-leverage-v3.md..." -cat > "$ANALYSIS_DIR/signal-cgm-final-ranking-leverage-v3.md" << 'ENDDOC' -# Signal CGM — Final Composite Ranking and Leverage Analysis v3 -### Asset Sale Primary · Pilot Secondary · MA + Medicaid Payer Scope -### STTIL Solutions LLC | April 2026 - ---- - -## Final Composite Ranking — Four Segments, MA + Medicaid Scope - -| Rank | Segment | Asset (×0.50) | Pilot (×0.30) | SaaS (×0.20) | Composite | -|------|---------|--------------|--------------|-------------|-----------| -| **#1** | Billing company / DME RCM | 3.60 | 2.46 | 1.55 | **7.61** | -| **#2** | NikoHealth-type platform | 4.28 | 2.13 | 0.93 | **7.34** | -| **#3** | VGM Group / MSO | 3.58 | 1.08 | 1.06 | **5.72** | -| **#4** | Mid-size independent supplier | 1.65 | 2.09 | 1.62 | **5.36** | - -**The 0.27-point gap between #1 and #2 is a sequencing signal, not a clear winner.** -Pilot with billing company → generate evidence → close NikoHealth asset sale at higher price. -These tracks are mutually reinforcing. - ---- - -## Denial Cost Absorption vs. Recovery — Full Quantification - -### Appeal Ladder Economics (Per ~$250 CGM Claim) - -| Level | Timeline | Staff Cost | Overturn Rate | Net Yield | -|-------|----------|-----------|--------------|-----------| -| L1 Redetermination | 60–74 days | $25–$55 | 20–30% | $22.50 net after labor | -| L2 QIC Reconsideration | 60 days | $50–$118 | 50–65% | $58.50 net after labor | -| L3 ALJ Hearing | 6–18 months | $200–$1,500+ | 60–70% | ($687.50) net LOSS per claim | -| L4–5 Council / Court | Years | $5K–$50K+ | Variable | Not viable for CGM refills | - -**MA-specific overlay:** MA L2 overturn rate is 63.9% (vs ~57% FFS) — but MA plans -deny more aggressively initially. Net: higher appeal labor per recovered dollar. - -### Absorption Model — 500-Patient Supplier, One Month - -``` -500 active CGM patients | $125,000/month billing | 25.2% improper payment rate - -126 denied claims (~$31,500 face value) - ├── 38 not appealed → written off immediately $9,500 - ├── 50 appealed at L1 only - │ ├── 13 overturned (~27%) $3,250 recovered - │ ├── 25 denied → abandoned $6,250 written off - │ └── 12 escalated to L2 - └── 38 at L2 total (12 escalated + 26 direct) - ├── 22 overturned (~57%) $5,500 recovered - └── 16 denied → written off $4,000 written off - -OUTCOME LEDGER: - Permanently written off (all paths): 79 claims $19,750 63% - Recovered through appeals: 35 claims $8,750 28% - Still in process: 12 claims $3,000 9% - - Appeal labor cost (88 filings): $5,192/month - Net recovery after labor: $8,750 − $5,192 = $3,558 - Net loss including labor: $19,750 + $5,192 = $24,942 - -ONE IN FIVE CGM BILLING DOLLARS IS PERMANENTLY LOST. -The appeal process recovers less than 30 cents of every denied dollar -after accounting for the staff labor required to run it. -``` - ---- - -## The Six Situations Where Suppliers Ship Despite Documentation Risk - -### Situation 1: The PA-Pending Ship -**What:** PA submitted but not yet affirmed. Refill due in 5 days. Supplier -ships assuming approval will come through. -**Frequency:** Very high — 14–21 day MAC adjudication window routinely overlaps -refill schedule for reactive workflows. -**Outcome if PA denied:** Non-covered denial. Zero recovery path. -**Signal CGM intervention:** PA initiated 45 days out. Order blocked until -PA confirmed. Ship date never collides with adjudication window. - -### Situation 2: The CMN Gray Zone -**What:** CMN expired 60 days ago. Doctor's office has been faxed three times. -Insulin-dependent patient is out of supplies. Supplier ships anyway. -**Frequency:** High. Physicians have 200 other patients. CMN renewal takes -60–90 days in slow practices. -**Outcome:** Denial. Backdated CMN rarely accepted at redetermination. -**Signal CGM intervention:** CMN expiration flagged 60 days out. Outreach -triggered at 45 days. Hold queue activates at 30 days if CMN not received. - -### Situation 3: The New-Code Gap -**What:** CMS adds codes to Required PA list (7 new codes April 13, 2026). -Staff not notified. Existing workflow processes orders normally. No PA obtained. -**Frequency:** Episodic but acute at each list expansion. Hypothesis 2 in -validation-hypotheses.md tests whether this gap is live and unpatched now. -**Outcome:** Non-covered denial. No recovery. -**Signal CGM intervention:** Required PA code list maintained current and -applied automatically to all open refill windows. - -### Situation 4: The PECOS Assumption -**What:** Prescriber was enrolled at intake 18 months ago. Practice changed. -PECOS lapsed. Supplier has no system to re-check at refill cycle. -**Frequency:** Moderate but growing. Practice instability post-COVID increasing. -**Outcome:** Hard denial. No appeal path if prescriber genuinely not enrolled. -**Signal CGM intervention:** NPPES checked at intake AND at each refill cycle. -Inactive NPI → order blocked → alert to supplier staff. - -### Situation 5: The Synapse Blindside -**What:** Patient on UHC Medicare Advantage. Valid UHC PA in hand. Unknown to -supplier: UHC transitioned patient's state to Synapse Health (April 1, 2026). -Supplier not enrolled in Synapse. PA obtained through UHC portal not valid -in Synapse-managed network. Order ships. Denied: not in authorized network. -**Frequency:** Acute. 20+ states now in Synapse territory as of April 2026. -**Outcome:** Network access denial. Difficult appeal — supplier must prove -non-notification. -**Signal CGM intervention:** Payer-plan tracking layer flags UHC MA patients -in Synapse-covered states. Verifies Synapse enrollment before shipment. - -### Situation 6: The Continuity Bridge -**What:** Coverage lapsed. Supplier working to restore. Patient calls: out of -sensors, insulin-dependent. Supplier provides bridge supplies with no active -PA, no valid CMN, no documentation. -**Frequency:** Low per patient; high consequence. The end state of situations -1–4 going unmanaged. -**Outcome:** Full product cost absorbed. No billing path. -**Signal CGM intervention:** Situations 1–4 never reach Situation 6 when -caught 45 days out. This situation is structurally prevented by the other five. - ---- - -## Workflow Leverage Analysis - -| Step | Financial Impact/Event | Frequency/Month | Preventability | Leverage Score | -|------|----------------------|----------------|----------------|----------------| -| **Prior Authorization** | $250 hard write-off; zero recovery path | HIGH: 15–25 at-risk refills in 500-pt book | HIGH: PA tracked 45 days out; ship blocked until confirmed | **9.2 / 10** | -| **Refill Tracking (Coverage Clock)** | Enables all other steps | HIGH: every active patient every month | HIGH: core calendar engine | **8.8 / 10** | -| **6-Month Visit Compliance** | $250/claim; 55% recoverable at L2 | MODERATE: 8–15 patients/month in mature book | HIGH: visit window calculated from refill date | **8.1 / 10** | -| **PECOS Validation** | $250 hard write-off; zero recovery | LOW: 2–5 events/month in 500-pt book | HIGH: NPPES checked at intake + each refill | **7.4 / 10** | -| **Intake Validation** | Prevents pipeline contamination | LOW: 5–15 new patients/month in mature book | HIGH: NPI, eligibility, base equipment, duplicates | **6.5 / 10** | -| **Audit Defense Log** | High if audit triggered ($50K–$500K) | LOW: episodic | MODERATE: time-stamped byproduct of all other steps | **5.8 / 10** | - -### The Leverage Verdict - -**Prior authorization is the single highest-leverage intervention point.** PA -failure = non-recoverable write-off. No appeal path. Zero exceptions. Every -other denial type has some theoretical recovery path. PA does not. - -**Refill tracking is the enabling infrastructure, not a standalone lever.** -Without knowing when the next order ships, nothing else is actionable. It is -the architecture, not a feature. - -**6-month visit compliance is the highest-frequency daily queue driver.** 8–15 -patients per month, every month, in a 500-patient mature book. Prevented before -shipment is worth more than 57% chance of recovery after denial. - -**Audit defense is the second story for asset sale conversations.** After daily -denial prevention, before competitive bidding urgency. In the current OIG -enforcement environment, "your customers can prove proactive compliance" is a -meaningful product differentiator. - ---- - -## Asset Sale One-Liner - -> "Signal CGM gives the buyer's customers 45 days to fix what would otherwise -> cost them 20% of their CGM revenue — and generates a compliance record that -> defends them against the government enforcement environment that's already active." - ---- - -## Sources -- [CMS 2024 CGM Improper Payments — 25.2% rate](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) -- [VGM DMEPOS Appeals Guide](https://www.vgm.com/communities/navigating-dmepos-appeals-processes-a-strategic-guide-for-providers/) -- [Denial Management Metrics](https://www.panahealthcaresolutions.com/blogs/denial-management-metrics-for-faster-reimbursement/) -- [Experian State of Claims 2025](https://www.experian.com/blogs/healthcare/state-of-claims-2025/) -- [KFF: MA Prior Authorization 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) -- [OIG CGM Enforcement Priority 2025](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) -- [UHC/Synapse Health Expansion — UHCprovider.com](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) -- [CGM Fraud Schemes — Qlarant](https://www.qlarant.com/knowledge/blog/continuous-glucose-monitor-fraud-schemes/) -- [Ossur Medicare Appeals Timeline Guide](https://www.ossur.com/en-us/professionals/ossur-rr/appealing-denied-medicare-claims-redetermination-reconsideration-and-alj) -ENDDOC -ok "signal-cgm-final-ranking-leverage-v3.md written" - -# ============================================================================= -# PITCH v1 — signal-cgm-pitch-v1-plain.md (Plain Language / Social Media) -# ============================================================================= -log "Writing signal-cgm-pitch-v1-plain.md..." -cat > "$ASSETS_DIR/signal-cgm-pitch-v1-plain.md" << 'ENDDOC' -# Signal CGM — Asset Sale Overview -## Plain Language Edition -### For Social Sharing and Non-Technical Decision Makers - ---- - -> SIGNAL CGM -> Stop Losing 20% of Your Clients' CGM Revenue. -> A ready-to-deploy tool for DME billing companies. -> STTIL Solutions LLC | kisasttil@gmail.com - ---- - -### The Problem. In Plain English. - -Right now, your clients are losing money they don't have to lose. - -For every $100 they bill on CGM (continuous glucose monitors), about **$20 -disappears.** It doesn't go to fraud. It doesn't go to bad patients. It goes -to paperwork that wasn't ready on time. - -A claim gets denied. The product was already shipped. The patient has it. Your -client can't get it back. They try to appeal. Most of the time, they lose more -money fighting it than they get back. - -Here's the part that stings: **94% of those denied claims could have been -prevented.** The information existed. Someone just didn't have it in hand -before the order shipped. - -That's what Signal CGM fixes. - ---- - -### What Goes Wrong — and When We Catch It - -There are six places in the workflow where a claim goes from "fine" to "denied." -We catch all six **before the product ships**, not after. - -**1. Prior Authorization — the biggest one.** -No PA before shipment = no money, period. No appeals, no second chances. We -make sure PA is confirmed 45 days before the order goes out the door. - -**2. The Coverage Clock.** -Every CGM patient has a refill schedule. We track it for every patient, every -month. This is the engine everything else runs on. - -**3. The 6-Month Doctor Visit.** -Medicare requires a check-in with the prescribing doctor every 6 months for -CGM patients to keep getting supplies. When that visit doesn't happen, the -claim gets denied. We flag it a month before it becomes a problem. - -**4. Prescriber Enrollment Check.** -If the doctor who ordered the CGM isn't currently enrolled in Medicare, the -claim gets denied — even if everything else is perfect. We re-check this every -time an order is about to ship, not just when the patient first signs up. - -**5. New Patient Setup.** -Before anyone's first order ships, we check eligibility, duplicate claims, and -whether the right supplier is on file with CMS. Bad setups become expensive -surprises later. - -**6. Audit Defense — the safety net.** -Every check we run gets logged with a time stamp. If CMS ever audits one of -your clients, that log shows exactly what was verified and when. It's proof -they were doing things right. - ---- - -### Try It First. On Your Own Client Data. - -We're offering a **60-day pilot** at no cost. - -Pick two to three of your suppliers. We run Signal CGM on their live CGM -patient data. We track what would have been denied. We show you what changed. - -At the end of 60 days, you'll see the before-and-after in your clients' actual -numbers — not in a demo, not in a made-up scenario. - -If it doesn't show a clear improvement in first-pass CGM claims, there's no deal. - ---- - -### What We're Asking - -Signal CGM is available two ways: - -**Option 1 — You own it.** -One-time purchase: **$45,000–$65,000.** -You get the full code, all the research, 30 days of live handoff sessions, and -the AI development context so your team can keep building. You white-label it. -You charge your clients. The revenue is yours. - -**Option 2 — Per-client licensing.** -**$75 per supplier client per month.** -If you have 20 CGM-active clients, that's $1,500/month. You pass the cost -through at whatever margin makes sense for your business. - ---- - -### Three Questions You're Probably Already Thinking - -**"Is this worth the cost?"** -Your clients are losing $20 of every $100 they bill on CGM. If Signal CGM -moves that to $14 lost instead of $20 — a modest improvement — a single -500-patient supplier recovers $9,000+ per month. At $75/month, that's a -120-to-1 return. The cost question answers itself. - -**"Doesn't this make my billing services less necessary?"** -No. Your clients still need you to run their billing, handle denials, and -manage payer relationships. Signal CGM handles the pre-shipment window — the -45 days before a claim exists. That's not your current job. It becomes a new -service you offer, not a replacement for what you already do. - -**"What happens to patient data?"** -Signal CGM never stores patient names, Social Security numbers, dates of birth, -or contact information. The only identifier the system uses is the supplier's -internal patient ID number. All audit logs hash even that. Data stays on your -infrastructure, not ours. A Business Associate Agreement is part of every -deployment. - ---- - -**Ready to run the pilot?** -Contact: kisasttil@gmail.com -STTIL Solutions LLC | Signal CGM - ---- - -*Key data: CMS 2024 CGM improper payment rate 25.2% / $278.5M projected annual.* -*Source: [CMS Glucose Monitoring Compliance](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies)* -ENDDOC -ok "signal-cgm-pitch-v1-plain.md written" - -# ============================================================================= -# PITCH v2 — signal-cgm-pitch-v2-professional.md (Professional) -# ============================================================================= -log "Writing signal-cgm-pitch-v2-professional.md..." -cat > "$ASSETS_DIR/signal-cgm-pitch-v2-professional.md" << 'ENDDOC' -# Signal CGM — Asset Sale Overview -## Professional Edition -### Strategic Acquisition for DME-Focused Revenue Cycle Management Organizations - ---- - -> SIGNAL CGM -> A CGM-Specific Denial Prevention and Compliance Intelligence Platform -> for DME Revenue Cycle Management Organizations -> -> Asset Acquisition and Licensing Opportunity | April 2026 -> STTIL Solutions LLC | kisasttil@gmail.com - ---- - -### The Problem Your Clients Cannot Solve Alone - -CMS's 2024 Medicare Fee-for-Service data puts the CGM improper payment rate at -**25.2% — $278.5 million in projected annual overpayments** on glucose monitor -billing. Of that figure, 94.2% traces directly to documentation deficiencies: -missing or expired Certificates of Medical Necessity, prior authorizations not -obtained before shipment, undocumented 6-month physician visits, and prescriber -PECOS enrollment failures. Less than 6% reflects medical necessity disputes or -coverage policy conflicts. - -The financial consequence for a supplier billing 500 active CGM patients monthly -runs deeper than the denial rate suggests. After accounting for appeal labor, -write-off timing, and the hard limits of the five-level Medicare appeals process, -**approximately 63% of denied CGM claim value is permanently absorbed** — not -recovered through redetermination or QIC reconsideration. The net effect on a -$125,000/month CGM billing book: a structural revenue loss of roughly $25,000 -per month, or **20% of gross CGM billing**, that does not appear as a line item -in any supplier's P&L but is reflected across AR aging, appeal staffing overhead, -and uncompensated product cost. - -This is the problem Signal CGM was built to eliminate — not by improving the -appeals process, but by making the appeals process unnecessary. - ---- - -### Six Workflow Leverage Points, in Priority Order - -**1. Prior Authorization Tracking (Highest Leverage — No Recovery Path if Missed)** -PA not obtained before CGM shipment is the only denial type with zero appeal -recovery. Signal CGM initiates PA tracking 45 days before the projected refill -date — sufficient runway for the MAC's 14–21 day adjudication window plus a -resubmission buffer — and blocks order release until PA is confirmed in the -system. The April 13, 2026 expansion of the Required Prior Authorization list -and ongoing MA plan-specific requirements (UHC non-T1D since September 2024) -are automatically reflected in the current HCPCS code tracking layer. - -**2. Refill Tracking / Coverage Clock (Enabling Architecture)** -A predictive refill calendar keyed to each patient's last dispense date, device -type, and payer-specific wear-day rules generates the operational foundation for -every other intervention point. Without forward visibility into the refill -schedule, PA initiation, CMN flagging, and visit compliance checks are reactive -lookups rather than automated workflow triggers. - -**3. 6-Month Physician Visit Compliance (Highest Frequency Preventable Denial)** -Medicare's continued CGM coverage requirement mandates a documented in-person -or telehealth visit with the treating practitioner every six months. In a mature -500-patient book, 8–15 patients per month are approaching or past this window. -Unlike PA failures, missed-visit denials carry a 50–65% QIC overturn rate when -documentation can be obtained retroactively — but preventing the denial is worth -more than recovering half of it post-filing. Signal CGM surfaces each patient's -visit window as a prioritized outreach task 30+ days before the refill date. - -**4. Prescriber PECOS Validation at Each Refill Cycle (Hard Write-Off Prevention)** -Medicare requires that the ordering physician maintain active enrollment at the -time each order is placed — not merely at the time of initial patient intake. -No incumbent DME billing platform currently re-validates prescriber enrollment -status at the refill cycle level. Signal CGM queries the NPPES registry against -the ordering provider's NPI at each scheduled refill and routes any inactive or -mismatched NPI to a supplier alert queue before the order can release. - -**5. Intake Validation (Pipeline Defense)** -At new patient intake, Signal CGM performs eligibility verification, duplicate -claim history check, base equipment record validation (M124), and initial -prescriber PECOS status check before any first order is authorized. - -**6. Audit Defense Log (Compliance Record as System Byproduct)** -Every pre-submission check generates a time-stamped audit log entry documenting -what was verified and when. In the current enforcement environment — with $1.9B -in DMEPOS improper payments under active OIG scrutiny, CGM explicitly identified -as a 2026 nationwide enforcement priority, and $1.8B in payments suspended by -CMS's Fraud Defense Operations Center in 2025 — a defensible compliance record -distinguishes a legitimate supplier from an audit target when the MAC issues an ADR. - ---- - -### The Pilot Offer: 60-Day Proof of Concept on Live Client Data - -We are offering a structured 60-day pilot at no cost or obligation. - -Select two to three CGM-active clients from your book. Signal CGM runs against -their live billing data — tracking open refills, flagging PA status gaps, CMN -expirations, and visit compliance windows across their active CGM patient roster. -At day 30 and day 60, we deliver a denial risk exposure report: claims that would -have shipped without documentation in hand, segmented by denial type and estimated -dollar exposure. - -The pilot does not require replacing or integrating with existing billing software. -Signal CGM operates as a parallel layer over whatever clearinghouse or platform -the client currently uses. PHI handling during the pilot is governed by a Business -Associate Agreement executed before data access begins. - -At the conclusion of 60 days, you hold a documented, client-specific before-and-after -comparison. That evidence either supports a deployment decision or it does not. -There is no obligation if the results do not meet your threshold. - ---- - -### The Ask - -**Option 1 — Full Asset Acquisition** -One-time acquisition: **$45,000–$65,000** - -Includes: full Python/FastAPI source code, coverage calculator, audit logger, -PostgreSQL data models, payer rules configuration, complete research library -(market research, compliance roadmap, BAA framework), 30-day live knowledge -transfer with the STTIL Solutions founder, and the CLAUDE.md AI development -context enabling immediate continuation of development with Claude Code at -zero ramp-up cost. No licensing fees, no royalties, no ongoing STTIL involvement -unless contracted separately. - -Buyer white-labels the product, deploys across their client base, and captures -the full downstream revenue. - -**Option 2 — Per-Seat Licensing** -**$75 per supplier client per month** (volume negotiable above 25 seats) - -Includes ongoing payer rule updates, Required PA code list maintenance, and -access to product improvements. A 20-client deployment at $75/month represents -$1,500/month in licensing cost against a conservative $9,000–$18,000/month in -recovered denial revenue across those clients — before accounting for staff -labor savings on appeal management. - ---- - -### Three Objections Addressed Directly - -**"The cost isn't justified at our current scale."** -The financial threshold for ROI is low. A single client with 300 active CGM -patients billing $75,000/month, running at the documented 25% improper payment -rate, absorbs approximately $11,200/month in net CGM write-offs after exhausting -the appeal process. If Signal CGM prevents 40% of those — the conservative end -of what pre-submission PA and CMN tracking demonstrably delivers — that client -recovers $4,500/month. Against a $75/month per-seat cost, that is a 60-to-1 -return on a single deployment. The 60-day pilot makes this calculation concrete -on your clients' actual numbers. - -**"This tool reduces the complexity that makes our billing services valuable."** -Signal CGM operates exclusively in the pre-submission window — the 45 days before -a claim exists. It does not touch denial management, appeals coordination, payer -negotiation, remittance reconciliation, or any other function that defines your -current service relationship. What it does is give your clients fewer denials to -manage, which reduces the reactive workload on your team without displacing any -service functions you bill for. The more accurate framing: Signal CGM converts -reactive denial management — which your staff absorbs at $50–$118 per appeal -cycle — into a proactive workflow your clients pay you a premium to maintain. -It is a service tier expansion, not a service substitution. - -**"We can't expose client PHI to a third-party system."** -Signal CGM was designed from the architecture level with this constraint as -non-negotiable. The system ingests five fields only: patient ID (the supplier's -internal account number, not a Medicare beneficiary identifier), device type, -shipment date, quantity, and payer code. No patient names, dates of birth, Social -Security numbers, diagnoses, or contact information enter the system at any point. -All audit logs hash even the patient ID before storage. The system is self-hosted -— it runs on your infrastructure or your client's infrastructure, not on STTIL's -servers. Data never transits a third-party network. The Business Associate -Agreement and full compliance documentation package are included in both -acquisition and licensing structures. - ---- - -**Next Step: Schedule the pilot conversation.** -kisasttil@gmail.com | STTIL Solutions LLC | Signal CGM - -*This document is a confidential business communication intended for the named -recipient only.* - ---- - -### Sources -- [CMS 2024 CGM Improper Payment Rate — 25.2% / $278.5M](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) -- [OIG 2025: CGM Payments Exceeded Supplier Costs](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) -- [Federal Authorities Targeting CGM Claims — National Law Review](https://natlawreview.com/article/federal-authorities-are-targeting-continuous-glucose-monitoring-cgm-device) -- [MA Prior Authorization Denial Rates — KFF 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) -- [UHC/Synapse Health DME Orders — UHCprovider.com](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) -- [CMS Prior Authorization Expansion April 13, 2026](https://www.hcintellect.com/post/medicare-dmepos-prior-authorization-expansion-effective-april-13-2026) -- [Denial Management Metrics](https://www.panahealthcaresolutions.com/blogs/denial-management-metrics-for-faster-reimbursement/) -ENDDOC -ok "signal-cgm-pitch-v2-professional.md written" - -# ============================================================================= -# MASTER SUMMARY -# ============================================================================= -log "Writing master-summary.md..." -cat > "$OUTPUT_DIR/master-summary.md" << 'ENDDOC' -# Signal CGM — Master Summary -### Strategic Analysis Package | STTIL Solutions LLC | April 2026 - ---- - -## What This Package Contains - -| File | Description | -|------|-------------| -| Analysis/signal-cgm-segment-scoring-v1.md | Three-model scoring: SaaS ICP, Asset Sale, Pilot Validation across 7 segments | -| Analysis/signal-cgm-re-scored-composite-v2.md | Composite re-score (50/30/20 weights) with MA + Medicaid payer scope applied | -| Analysis/signal-cgm-final-ranking-leverage-v3.md | Final four-segment ranking, denial quantification, six leverage points | -| Assets/signal-cgm-pitch-v1-plain.md | Leave-behind: plain language / social media (6th grade reading level) | -| Assets/signal-cgm-pitch-v2-professional.md | Leave-behind: professional (mid-size and larger billing organizations) | - ---- - -## Final Composite Rankings (MA + Medicaid Scope · Asset Sale Primary) - -| Rank | Segment | Composite Score | Primary Use | -|------|---------|----------------|-------------| -| #1 | Billing company / DME RCM outsourcer | **7.61** | Pilot partner + asset buyer | -| #2 | NikoHealth-type platform vendor | **7.34** | Primary asset sale target | -| #3 | VGM Group / MSO | **5.72** | Follow-on distribution post-sale | -| #4 | Mid-size independent supplier | **5.36** | SaaS ICP if pivot away from asset sale | - -**Weights:** Asset sale 50% · Pilot 30% · SaaS 20% - ---- - -## Key Metrics (All Sources: CMS 2024 / OIG 2025 / KFF 2024) - -| Metric | Value | -|--------|-------| -| CGM improper payment rate (Medicare) | 25.2% | -| Projected annual CGM improper payments | $278.5M | -| Share from documentation failures | 94.2% | -| Net revenue loss after appeals (per supplier) | ~20% of gross CGM billing | -| Permanently written off (not recovered) | ~63% of denied claim value | -| Recovered through L1+L2 appeals | ~28% of denied claim value | -| MA DMEPOS appeal success rate (L2) | 63.9% | -| MA prior auth denial rate | 7.7% of PA requests | -| Traditional HME supplier locations (2024) | ~8,005 (−38% from 2013) | - ---- - -## Leverage Priority Stack (Workflow Intervention Points) - -1. **Prior Authorization** (9.2/10) — Only denial type with zero recovery path -2. **Refill Tracking / Coverage Clock** (8.8/10) — Enabling infrastructure for everything -3. **6-Month Visit Compliance** (8.1/10) — Highest-frequency daily queue driver -4. **PECOS Validation at Each Refill** (7.4/10) — Hard write-off prevention -5. **Intake Validation** (6.5/10) — Front-door pipeline defense -6. **Audit Defense Log** (5.8/10) — Compliance record as system byproduct - ---- - -## Sequencing Recommendation - -``` -Week 1–2: Identify 2–3 billing company targets with CGM-active client books -Week 2–4: Approach with Version 1 or 2 leave-behind; propose 60-day pilot -Week 4–8: Execute pilot on live MA + Medicaid CGM data under BAA -Week 8: Deliver denial risk exposure report (before/after) -Week 9–12: Use pilot evidence to open NikoHealth asset sale conversation - at higher valuation than current $45K–$65K ask -Week 12+: Parallel VGM vendor partner program conversation for distribution -``` - ---- - -## Validated Hypotheses Status (as of April 2026) - -| Hypothesis | Status | Method | -|-----------|--------|--------| -| H1: Denials are documentation-fixable | **Confirmed by CMS data** — 94.2% doc failures | Desk research (OIG + CMS 2024) | -| H2: April 13 PA expansion is live and unpatched | **Likely confirmed** — no incumbent updated | Requires 2–3 discovery calls to verify | -| H3: CB 2028 deadline drives active buying urgency | **Untested** | Requires 5 discovery calls with owner-operators | - ---- - -## Next-Steps Prompt for Next Claude Code Session - -> Continue Signal CGM go-to-market execution. All strategic analysis is -> in CGM-Denial-Prevention/01-Claude-Outputs/. The asset sale target ranking -> is: #1 Billing company (pilot first), #2 NikoHealth (asset sale after pilot -> evidence). Payer scope: Medicare Advantage and Medicaid as first -> proof-of-concept. Pilot offer: 60 days, no cost, on live client data under -> BAA. Asset ask: $45K–$65K acquisition or $75/client/month licensing. -> Next priority: identify 3 billing company targets (suggest starting with -> Florida-based DME RCM firms given existing FAHCS research) and prepare -> outreach sequence using Assets/signal-cgm-pitch-v2-professional.md. -> Hypothesis H2 (April 13 PA gap) and H3 (CB urgency) still require -> discovery call validation per validation-hypotheses.md in Obsidian vault. - ---- - -*Generated: April 2026 | STTIL Solutions LLC | Signal CGM* -*All figures from CMS, OIG, KFF primary sources — see individual files for citations* -ENDDOC -ok "master-summary.md written" - -# ============================================================================= -# Step 6: Git Operations -# ============================================================================= -echo "" -echo " ── Git Operations ──────────────────────────────────────────────" -cd "$REPO_ROOT" - -# Verify git repo -git rev-parse --git-dir > /dev/null 2>&1 || fail "Not a git repository: $REPO_ROOT" - -# Stage the new directory -log "Staging CGM-Denial-Prevention/..." -git add CGM-Denial-Prevention/ - -# Check if there is anything to commit -if git diff --cached --quiet; then - ok "Nothing new to commit — files already tracked and unchanged" -else - log "Committing..." - git commit -m "$(cat <<'MSG' -feat: Signal CGM strategic analysis + asset sale package - -Adds complete go-to-market analysis for Signal CGM asset sale: - -Analysis/ - - signal-cgm-segment-scoring-v1.md (3-model scoring across 7 segments) - - signal-cgm-re-scored-composite-v2.md (50/30/20 composite, MA+Medicaid scope) - - signal-cgm-final-ranking-leverage-v3.md (final 4-segment rank + leverage map) - -Assets/ - - signal-cgm-pitch-v1-plain.md (plain language leave-behind) - - signal-cgm-pitch-v2-professional.md (professional leave-behind) - - master-summary.md (rankings, metrics, next-steps prompt) - -Key findings: 25.2% CGM improper payment rate; 20% net revenue loss; -63% of denied claims permanently written off; billing company #1 target -for pilot; NikoHealth #1 for asset sale. - -Co-Authored-By: Claude Sonnet 4.6 -MSG -)" - ok "Committed" - - # Push - log "Pushing to origin..." - if git push 2>&1; then - ok "Pushed to origin" - else - echo " ⚠ Push failed — changes are committed locally. Run 'git push' manually." - echo " (This is non-fatal; all files are written and committed.)" - fi -fi - -# ============================================================================= -# Step 7: Obsidian Sync -# ============================================================================= -echo "" -echo " ── Obsidian Sync ───────────────────────────────────────────────" - -if [ -d "$(dirname "$OBSIDIAN_DIR")" ]; then - log "Creating Obsidian target directory..." - mkdir -p "$OBSIDIAN_DIR" - - log "Syncing Analysis files..." - cp "$ANALYSIS_DIR/"*.md "$OBSIDIAN_DIR/" - - log "Syncing Assets files..." - cp "$ASSETS_DIR/"*.md "$OBSIDIAN_DIR/" - - log "Syncing master-summary.md..." - cp "$OUTPUT_DIR/master-summary.md" "$OBSIDIAN_DIR/" - - ok "Obsidian vault synced → $OBSIDIAN_DIR" -else - echo " ⚠ Obsidian vault path not found: $(dirname "$OBSIDIAN_DIR")" - echo " Skipping Obsidian sync — all files are in $OUTPUT_DIR" -fi - -# ============================================================================= -# Done -# ============================================================================= -echo "" -echo "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━" -echo "✅ All assets captured" -echo "" -echo " Output directory : $OUTPUT_DIR" -echo " Obsidian sync : $OBSIDIAN_DIR" -echo "" -echo " Files written:" -echo " Analysis/signal-cgm-segment-scoring-v1.md" -echo " Analysis/signal-cgm-re-scored-composite-v2.md" -echo " Analysis/signal-cgm-final-ranking-leverage-v3.md" -echo " Assets/signal-cgm-pitch-v1-plain.md" -echo " Assets/signal-cgm-pitch-v2-professional.md" -echo " master-summary.md" -echo "━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━" diff --git a/docs/design-tokens-v1.json b/docs/design-tokens-v1.json new file mode 100644 index 0000000..1a39682 --- /dev/null +++ b/docs/design-tokens-v1.json @@ -0,0 +1,200 @@ +{ + "$schema": "https://design-tokens.github.io/community-group/format/", + "$metadata": { + "version": "1.0.0", + "updated": "2026-04-23", + "scope": "STTIL Solutions — master token set (Signal CGM product expression)", + "accent-family": "tangerine" + }, + + "color": { + "teal": { + "50": { "$value": "#EEF8F8", "$type": "color", "$description": "Background washes, hover states" }, + "100": { "$value": "#CBE9E9", "$type": "color", "$description": "Bordered containers, soft highlights" }, + "200": { "$value": "#97D3D3", "$type": "color", "$description": "Disabled interactive elements" }, + "300": { "$value": "#5BBBBB", "$type": "color", "$description": "Secondary text on dark backgrounds" }, + "400": { "$value": "#2EA3A3", "$type": "color", "$description": "Icon fills, chart secondary series; primary brand in dark mode" }, + "500": { "$value": "#1A8A8A", "$type": "color", "$description": "Primary interactive, links" }, + "600": { "$value": "#147A7A", "$type": "color", "$description": "Brand primary — dominant system color (light mode)" }, + "700": { "$value": "#0F5E5E", "$type": "color", "$description": "Hover state on teal-600; wordmark color on light" }, + "800": { "$value": "#0A4444", "$type": "color", "$description": "Elevated panels in dark mode" }, + "900": { "$value": "#072E2E", "$type": "color", "$description": "Sidebar, card surface in dark mode" }, + "950": { "$value": "#041A1A", "$type": "color", "$description": "Page background in dark mode (AMOLED-deep)" } + }, + + "tangerine": { + "50": { "$value": "#FFF4EE", "$type": "color", "$description": "Tangerine wash (use rarely)" }, + "100": { "$value": "#FFE4CC", "$type": "color", "$description": "Call-out block backgrounds; PA Required badge fill (light)" }, + "200": { "$value": "#FFC090", "$type": "color", "$description": "Light tangerine for illustration accents" }, + "300": { "$value": "#FFB070", "$type": "color", "$description": "Warm glow text on dark surfaces — promoted" }, + "400": { "$value": "#F07840", "$type": "color", "$description": "Borders, glows, active states on dark surfaces — promoted" }, + "500": { "$value": "#E06028", "$type": "color", "$description": "Primary accent in light mode" }, + "600": { "$value": "#C04E1C", "$type": "color", "$description": "Hover state on tangerine-500" }, + "700": { "$value": "#903A14", "$type": "color", "$description": "Text on tangerine-100 backgrounds; AA-safe" }, + "800": { "$value": "#6A2A0C", "$type": "color", "$description": "Deep tangerine for rare decorative use" }, + "900": { "$value": "#3E1808", "$type": "color", "$description": "Near-black tangerine" } + }, + + "neutral": { + "0": { "$value": "#FFFFFF", "$type": "color", "$description": "Card surfaces, pure white" }, + "50": { "$value": "#F4F9F9", "$type": "color", "$description": "Page background — light mode" }, + "100": { "$value": "#E5EEEE", "$type": "color", "$description": "Dividers, table row alternates" }, + "200": { "$value": "#C8D8D8", "$type": "color", "$description": "Borders, input outlines" }, + "300": { "$value": "#A3BEBE", "$type": "color", "$description": "Placeholder text, disabled" }, + "400": { "$value": "#7A9E9E", "$type": "color", "$description": "Secondary body text" }, + "500": { "$value": "#5A7E7E", "$type": "color", "$description": "Body text minimum on white" }, + "600": { "$value": "#426060", "$type": "color", "$description": "Strong body text (light surfaces only)" }, + "700": { "$value": "#2E4444", "$type": "color", "$description": "Headings on light" }, + "800": { "$value": "#1C2C2C", "$type": "color", "$description": "Primary text on light" }, + "900": { "$value": "#111A1A", "$type": "color", "$description": "Maximum contrast (light mode only)" } + }, + + "semantic": { + "success": { + "100": { "$value": "#C8EDD8", "$type": "color" }, + "500": { "$value": "#1A7A4E", "$type": "color", "$description": "Active coverage, completed actions" }, + "600": { "$value": "#146040", "$type": "color", "$description": "Text on success-100 backgrounds" } + }, + "warning": { + "100": { "$value": "#FDECD5", "$type": "color" }, + "400": { "$value": "#D97B35", "$type": "color", "$description": "Expiring soon (30–59 days)" }, + "600": { "$value": "#A85A18", "$type": "color", "$description": "Critical expiry (<30 days); text on warning-100" } + }, + "error": { + "100": { "$value": "#F8CCCC", "$type": "color" }, + "500": { "$value": "#C83030", "$type": "color", "$description": "Denied, expired, destructive actions" }, + "600": { "$value": "#A02020", "$type": "color", "$description": "Text on error-100 backgrounds" } + }, + "info": { + "100": { "$value": "#C8E0EE", "$type": "color" }, + "500": { "$value": "#1A6A9A", "$type": "color", "$description": "Informational, pending review" } + }, + "purple": { + "100": { "$value": "#E2D8F0", "$type": "color" }, + "500": { "$value": "#7A5EA0", "$type": "color", "$description": "PA pending, in-process states" } + } + }, + + "mode": { + "dark": { + "bg-page": { "$value": "#041A1A", "$type": "color" }, + "bg-card": { "$value": "#072E2E", "$type": "color" }, + "bg-elevated": { "$value": "#0A4444", "$type": "color" }, + "text-heading": { "$value": "#FFFAF6", "$type": "color", "$description": "Warm white — slightly copper-tinted vs pure white" }, + "text-primary": { "$value": "#F0F4F4", "$type": "color", "$description": "Softened body text — not stark white" }, + "text-secondary":{ "$value": "#5BBBBB", "$type": "color" }, + "text-muted": { "$value": "#5A8080", "$type": "color", "$description": "Min AA-safe on teal-950; ~4.2:1" }, + "border": { "$value": "#0F5E5E", "$type": "color" }, + "brand": { "$value": "#2EA3A3", "$type": "color", "$description": "teal-400 — shifted up from teal-600 for dark contrast" }, + "accent": { "$value": "#F07840", "$type": "color", "$description": "tangerine-400 — warm glow on dark" }, + "accent-text": { "$value": "#FFB070", "$type": "color", "$description": "tangerine-300 — gold text on dark" } + }, + "light": { + "bg-page": { "$value": "#F4F9F9", "$type": "color" }, + "bg-card": { "$value": "#FFFFFF", "$type": "color" }, + "bg-elevated": { "$value": "#E5EEEE", "$type": "color" }, + "text-heading": { "$value": "#0A3030", "$type": "color", "$description": "Deep teal-charcoal heading" }, + "text-primary": { "$value": "#1C2E2E", "$type": "color", "$description": "Deep charcoal — not stark black" }, + "text-secondary":{ "$value": "#5A7E7E", "$type": "color" }, + "text-muted": { "$value": "#7A9E9E", "$type": "color" }, + "border": { "$value": "#C8D8D8", "$type": "color" }, + "brand": { "$value": "#147A7A", "$type": "color" }, + "accent": { "$value": "#E06028", "$type": "color", "$description": "tangerine-500 — restrained on light" }, + "accent-text": { "$value": "#E06028", "$type": "color" } + } + } + }, + + "typography": { + "fontFamily": { + "heading": { "$value": "'Plus Jakarta Sans', sans-serif", "$type": "fontFamily" }, + "body": { "$value": "'Inter', sans-serif", "$type": "fontFamily" }, + "mono": { "$value": "'JetBrains Mono', monospace", "$type": "fontFamily" } + }, + "fontSize": { + "xs": { "$value": "0.75rem", "$type": "dimension", "$description": "12px" }, + "sm": { "$value": "0.875rem", "$type": "dimension", "$description": "14px" }, + "base": { "$value": "1rem", "$type": "dimension", "$description": "16px" }, + "lg": { "$value": "1.125rem", "$type": "dimension", "$description": "18px" }, + "xl": { "$value": "1.25rem", "$type": "dimension", "$description": "20px" }, + "2xl": { "$value": "1.5rem", "$type": "dimension", "$description": "24px" }, + "3xl": { "$value": "1.875rem", "$type": "dimension", "$description": "30px" }, + "4xl": { "$value": "2.25rem", "$type": "dimension", "$description": "36px" }, + "5xl": { "$value": "3rem", "$type": "dimension", "$description": "48px" } + }, + "fontWeight": { + "regular": { "$value": 400, "$type": "fontWeight" }, + "medium": { "$value": 500, "$type": "fontWeight" }, + "semibold":{ "$value": 600, "$type": "fontWeight" }, + "bold": { "$value": 700, "$type": "fontWeight" } + }, + "lineHeight": { + "tight": { "$value": 1.15, "$type": "number" }, + "snug": { "$value": 1.25, "$type": "number" }, + "normal": { "$value": 1.5, "$type": "number" }, + "relaxed": { "$value": 1.6, "$type": "number" } + }, + "letterSpacing": { + "tight": { "$value": "-0.02em", "$type": "dimension" }, + "normal": { "$value": "0em", "$type": "dimension" }, + "wide": { "$value": "0.05em", "$type": "dimension" }, + "wider": { "$value": "0.08em", "$type": "dimension" }, + "widest": { "$value": "0.1em", "$type": "dimension" } + } + }, + + "spacing": { + "0": { "$value": "0rem", "$type": "dimension" }, + "1": { "$value": "0.25rem","$type": "dimension", "$description": "4px" }, + "2": { "$value": "0.5rem", "$type": "dimension", "$description": "8px" }, + "3": { "$value": "0.75rem","$type": "dimension", "$description": "12px" }, + "4": { "$value": "1rem", "$type": "dimension", "$description": "16px" }, + "5": { "$value": "1.25rem","$type": "dimension", "$description": "20px" }, + "6": { "$value": "1.5rem", "$type": "dimension", "$description": "24px" }, + "8": { "$value": "2rem", "$type": "dimension", "$description": "32px" }, + "10": { "$value": "2.5rem", "$type": "dimension", "$description": "40px" }, + "12": { "$value": "3rem", "$type": "dimension", "$description": "48px" }, + "16": { "$value": "4rem", "$type": "dimension", "$description": "64px" }, + "20": { "$value": "5rem", "$type": "dimension", "$description": "80px" }, + "24": { "$value": "6rem", "$type": "dimension", "$description": "96px" } + }, + + "borderRadius": { + "none": { "$value": "0", "$type": "dimension" }, + "sm": { "$value": "0.25rem", "$type": "dimension", "$description": "4px" }, + "md": { "$value": "0.5rem", "$type": "dimension", "$description": "8px" }, + "lg": { "$value": "0.75rem", "$type": "dimension", "$description": "12px" }, + "xl": { "$value": "1rem", "$type": "dimension", "$description": "16px" }, + "2xl": { "$value": "1.5rem", "$type": "dimension", "$description": "24px" }, + "full": { "$value": "9999px", "$type": "dimension" } + }, + + "shadow": { + "sm": { "$value": "0 1px 3px rgba(7,46,46,0.10)", "$type": "shadow" }, + "md": { "$value": "0 2px 10px rgba(4,26,26,0.14)", "$type": "shadow" }, + "lg": { "$value": "0 4px 20px rgba(4,26,26,0.18)", "$type": "shadow" }, + "xl": { "$value": "0 8px 32px rgba(4,26,26,0.22)", "$type": "shadow" }, + "tangerine-glow-dark": { "$value": "0 0 24px rgba(240,120,64,0.30), 0 2px 10px rgba(4,26,26,0.70)", "$type": "shadow", "$description": "Premium card glow — dark mode only. One per view." }, + "tangerine-glow-light": { "$value": "0 0 16px rgba(224,96,40,0.20), 0 2px 8px rgba(0,0,0,0.08)", "$type": "shadow", "$description": "Premium card glow — light mode." } + }, + + "semantic-ui": { + "badge": { + "active": { "bg": "#C8EDD8", "text": "#146040", "icon": "✓" }, + "expiring": { "bg": "#FDECD5", "text": "#A85A18", "icon": "⚠" }, + "critical": { "bg": "#F8CCCC", "text": "#A02020", "icon": "⚠" }, + "pa-required":{ "bg": "#FFE4CC", "text": "#903A14", "icon": "⚡", "border": "rgba(144,58,20,0.2)" }, + "pa-pending": { "bg": "#E2D8F0", "text": "#7A5EA0", "icon": "○" }, + "denied": { "bg": "#F8CCCC", "text": "#A02020", "icon": "✕" }, + "info": { "bg": "#C8E0EE", "text": "#1A6A9A", "icon": "ℹ" } + }, + "sparkle": { + "priority-row-bg-dark": { "$value": "rgba(224,104,48,0.09)", "$description": "Highest-priority worklist row — dark mode" }, + "priority-row-bg-light": { "$value": "rgba(224,96,40,0.05)", "$description": "Highest-priority worklist row — light mode" }, + "tangerine-border-dark": { "$value": "1px solid #F07840", "$description": "Featured card edge on dark surface" }, + "tangerine-shimmer-border":{ "$value": "1px solid rgba(240,120,64,0.35)", "$description": "Subtle shimmer on elevated panels" }, + "active-nav-tangerine": { "$value": "3px solid #F07840", "$description": "Active sidebar nav left border" }, + "warm-white": { "$value": "#FFFAF6", "$description": "Heading text on dark teal — slightly warm vs pure white" } + } + } +} diff --git a/Projects/Compliance/hipaa-deployment-analysis-v1.md b/docs/hipaa-deployment-analysis-v1.md similarity index 100% rename from Projects/Compliance/hipaa-deployment-analysis-v1.md rename to docs/hipaa-deployment-analysis-v1.md diff --git a/docs/signal-brand-extension-v1.md b/docs/signal-brand-extension-v1.md new file mode 100644 index 0000000..a96fa64 --- /dev/null +++ b/docs/signal-brand-extension-v1.md @@ -0,0 +1,168 @@ +# Signal CGM — Brand Extension v1 + +**Date:** April 2026 +**Parent system:** `sttil-brand-system-v1.md` +**Status:** Active + +--- + +## 1. Inheritance from STTIL Solutions + +Signal CGM is a product expression of the STTIL Solutions brand. It inherits: +- Full teal scale (teal-950 → teal-50) +- Full tangerine scale as accent +- Plus Jakarta Sans / Inter / JetBrains Mono type stack +- All semantic status colors +- All spacing, radius, and shadow tokens +- "Never loud, always clear" visual principle + +**What shifts for Signal CGM:** +- Clinical precision takes priority over narrative warmth +- Data density is higher — tables and status indicators are the primary surface +- Urgency communication is more explicit (regulatory deadlines, expiry countdowns) +- Dark mode is the operational default (dashboard use) +- Tangerine appears at the PA Required badge and highest-priority row — the two highest-stakes signals in the UI + +--- + +## 2. Tone Shift + +| STTIL Solutions | Signal CGM | +|----------------|-----------| +| Warm, narrative, brand story | Precise, operational, clinical | +| Speaks to the vision | Speaks to the daily task | +| "Built for people bearing real operational weight" | "PT-00142 · 4 days left · PA Required" | +| Earns trust through specificity | Earns trust through accuracy | + +Signal CGM copy should read like a knowledgeable billing colleague, not a software vendor. + +--- + +## 3. Dashboard / UI Palette + +### Dark Mode (Operational Default) + +| Element | Token | Hex | +|---------|-------|-----| +| Page background | `teal-950` | `#041A1A` | +| Card / panel | `teal-900` | `#072E2E` | +| Elevated surface / table header | `teal-800` | `#0A4444` | +| Heading text | `warm-white` | `#FFFAF6` | +| Primary body text | `text-primary-dark` | `#F0F4F4` | +| Secondary text | `teal-300` | `#5BBBBB` | +| Muted / metadata text | `muted-dark` | `#5A8080` | +| Border | `teal-700` | `#0F5E5E` | +| Row divider | `teal-700 at 45%` | `rgba(15,94,94,0.45)` | +| Primary brand / interactive | `teal-400` | `#2EA3A3` | +| Tangerine accent (borders/glows) | `tangerine-400` | `#F07840` | +| Tangerine text (gold) | `tangerine-300` | `#FFB070` | +| Tangerine glow shadow | `shadow.tangerine-glow-dark` | see tokens | +| Priority row wash | `sparkle.priority-row-bg-dark` | `rgba(224,104,48,0.09)` | + +### Light Mode (Review / Export / Presentation) + +| Element | Token | Hex | +|---------|-------|-----| +| Page background | `neutral-50` | `#F4F9F9` | +| Card / panel | `neutral-0` | `#FFFFFF` | +| Elevated surface | `neutral-100` | `#E5EEEE` | +| Heading text | `text-heading-light` | `#0A3030` | +| Primary body text | `text-primary-light` | `#1C2E2E` | +| Secondary text | `neutral-500` | `#5A7E7E` | +| Muted | `neutral-400` | `#7A9E9E` | +| Border | `neutral-200` | `#C8D8D8` | +| Primary brand | `teal-600` | `#147A7A` | +| Tangerine accent | `tangerine-500` | `#E06028` | +| Priority row wash | `sparkle.priority-row-bg-light` | `rgba(224,96,40,0.05)` | + +--- + +## 4. CTA / Button Colors + +| Button | Dark Mode | Light Mode | Usage | +|--------|-----------|------------|-------| +| Primary action | `teal-400` fill, `warm-white` label | `teal-600` fill, white label | "Initiate Outreach," "Export CSV" | +| High-urgency action | `transparent`, `tangerine-400` border, `tangerine-300` label | `transparent`, `tangerine-500` border, `tangerine-500` label | "Initiate PA →" — one per view | +| Ghost / secondary | `transparent`, `teal-700` border, `teal-300` label | `transparent`, `neutral-200` border, `neutral-500` label | "View," "Follow Up" | +| Destructive | `error-500` at 15% fill, `#FF7070` label | `error-100` fill, `error-600` label | "Mark Denied," "Archive" | + +**Rule:** The tangerine CTA (PA action) appears at most once per screen. It is the most urgent action visible. + +--- + +## 5. Status / Alert Colors — Healthcare Workflow + +| Status | Icon | Light Badge | Dark Badge | When to Use | +|--------|------|-------------|------------|-------------| +| Active | ✓ | `success-100` bg / `success-600` text | `rgba(26,122,78,0.16)` / `#4AE899` | Coverage current, no action needed | +| Expiring Soon | ⚠ | `warning-100` / `warning-600` | `rgba(168,90,24,0.16)` / `#F0B464` | 30–59 days remaining | +| Critical Expiry | ⚠ | `error-100` / `error-600` | `rgba(200,48,48,0.16)` / `#FF7070` | < 30 days remaining | +| PA Required | ⚡ | `tangerine-100` / `tangerine-700` | `rgba(240,120,64,0.18)` / `#FFB070` | PA must be initiated | +| PA Pending | ○ | `purple-100` / `purple-500` | `rgba(122,94,160,0.16)` / `#C0A8E0` | PA submitted, awaiting affirmation | +| Denied | ✕ | `error-100` / `error-600` | `rgba(200,48,48,0.22)` / `#FF7070` | Claim denied — appeal path | +| Info | ℹ | `info-100` / `info-500` | `rgba(26,106,154,0.16)` / `#64B0D8` | Notes, system messages | + +**Non-negotiable:** Every badge must use icon + label. Never color alone as the sole status indicator. + +--- + +## 6. Worklist Table Conventions + +- **Patient ID column:** JetBrains Mono, `font-weight: 700`. On priority row, color shifts to `tangerine-300` (#FFB070 dark) or `tangerine-700` (#903A14 light). +- **Priority Score:** JetBrains Mono, 16px, `font-weight: 500`. High (≥75): tangerine-text. Mid (40–74): text-secondary. Low (<40): text-muted. +- **Days Left:** JetBrains Mono. Critical (<30): error red. Warning (30–59): tangerine-text. OK (60+): text-primary. +- **Top priority row:** One `priority-row-bg` wash + `★ TOP PRIORITY` micro-label in tangerine-text. Only one per view. +- **Tangerine CTA:** Only on the top priority row's action button. +- **Table header:** `teal-800` background, uppercase `text-muted` labels at `font-size: 10.5px`, `letter-spacing: 0.06em`. + +--- + +## 7. Pitch Deck Usage (Supplier-Facing) + +**Slide structure:** +- Title / section slides: `teal-900` background, `warm-white` headline, `teal-300` sub-label +- Content slides: `neutral-0` background, `teal-700` section headers +- Data charts: `teal-500` primary series, `tangerine-400` for the key comparison metric +- Call-out boxes: `tangerine-100` background, `tangerine-700` text, `tangerine-500` left border (4px) +- The two-curve workload graph (appeals ↓ / proactive outreach flat) is the hero visual + +**Supplier-facing language:** +- Lead with the denial rate: "35–45% first-pass denial rate for CGM claims" +- Show the crossover point: "Month 4 — proactive outreach volume replaces appeals volume" +- No AI language. No "platform." Call it a worklist tool. + +--- + +## 8. LinkedIn / Social Posts + +**Format — Signal CGM announcement post:** +- Carousel: 5 slides (hook → problem data → product shot → outcome → CTA) +- Cover slide: `teal-900` background, `warm-white` headline in Plus Jakarta Sans 700, one tangerine data point +- Data slides: `neutral-0` background, teal headers, JetBrains Mono for percentages +- One tangerine accent per slide — never two +- CTA slide: `teal-600` background, white text, simple ask + +**Tone:** Specific, grounded, no hype. Use actual regulatory dates and denial rates. + +--- + +## 9. Billing Company-Facing vs. Supplier-Facing Materials + +| Dimension | Supplier-Facing | Billing Company-Facing | +|-----------|----------------|----------------------| +| Primary pain | "My staff is buried in appeals" | "Our clients have high denial rates costing us rework" | +| Value frame | Prevent denials before they happen | Offer clients a differentiated CGM compliance tool | +| Regulatory hook | CMS competitive bidding deadline, PA affirmation rate | Same — but also enrollment moratorium / compliance risk | +| Product language | "Signal CGM worklist" | "Signal CGM — white-label ready" (future Phase 2) | +| Visual tone | Warm, operational, data-dense | Colder, more corporate, teal-900 dominant | +| CTA | "Try it with your next CSV import" | "Schedule a 30-minute walkthrough" | + +--- + +## 10. PHI Note on All Materials + +All Signal CGM marketing materials must include, at minimum in footer or fine print: + +> "Signal CGM does not store patient names, dates of birth, or contact information. Only patient_id (your internal MRN or account number) is used as the crosswalk key." + +This is a trust signal, not a legal disclaimer. Put it where a billing manager will see it. diff --git a/docs/sttil-brand-system-v1.md b/docs/sttil-brand-system-v1.md new file mode 100644 index 0000000..b24bdfe --- /dev/null +++ b/docs/sttil-brand-system-v1.md @@ -0,0 +1,376 @@ +# STTIL Solutions — Master Brand System v1 + +**Date:** April 2026 +**Status:** Active — Canonical Reference +**Scope:** STTIL Solutions (parent), Signal (product), STTIL Journeys (media layer) + +--- + +## 1. Brand Essence + +**STTIL = Speak the Truth in Love** + +This is the operating principle, not a tagline. Everything built under the STTIL name should: + +1. Be truthful — data-accurate, no inflated claims, no vague promises +2. Be intelligent — specialist-level thinking applied to real problems +3. Be grounded in care — built for people bearing real operational weight + +The brand earns trust through specificity. It does not perform warmth. It demonstrates it. + +--- + +## 2. Brand Architecture + +| Layer | Entity | Role | +|-------|--------|------| +| Parent | STTIL Solutions LLC | B2B health-tech infrastructure company | +| Product | Signal Powered by STTIL Solutions (commonly "Signal") | CGM billing intelligence for DMEPOS suppliers | +| Media | STTIL Journeys | Narrative/content expression of the STTIL story | + +**STTIL Solutions** is the credential — invoices, contracts, LinkedIn. +**Signal** (formally "Signal Powered by STTIL Solutions") is the product — what suppliers and billing teams use daily. Use "Signal" in product-facing contexts; use the full name in contracts, formal proposals, and first introductions. +**STTIL Journeys** is the voice — seasonal latitude, never departing from parent brand integrity. + +--- + +## 3. Positioning + +**STTIL Solutions:** +> Precision health-tech infrastructure for independent DMEPOS suppliers. Built to reduce claim denials, protect cash flow, and keep small suppliers viable in a tightening regulatory environment. + +Not a generic software company. A specialist that understands CMS coding, PA workflows, and the cash flow math of competitive bidding. + +**Signal** (Signal Powered by STTIL Solutions): +> The CGM coverage worklist that prevents denials before they happen. + +See full product brand extension: `signal-cgm-brand-extension-v1.md` + +**STTIL Journeys:** +> The human story behind the technology — health, resilience, and what it means to build in health-tech. + +More expressive. Seasonal palette allowed. Always tethered to the parent type and spacing system. + +--- + +## 4. Tone Attributes + +| Attribute | Means in Practice | Never | +|-----------|-------------------|-------| +| **Truthful** | Claims backed by data, specifics over superlatives | "Game-changing," "revolutionary," "disrupting" | +| **Grounded** | Speaks to the actual daily problem | Vague aspirational copy | +| **Precise** | Uses industry terminology correctly (PA, HCPCS, CMS, wear days) | Dumbed-down language that alienates buyers | +| **Warm** | Accessible; not clinical or robotic | Sappy, emotional manipulation, generic empathy | +| **Confident** | Makes clear positions | Overqualifying to the point of paralysis | +| **Urgent when appropriate** | Regulatory pressure is real; name it directly | False urgency, manufactured scarcity | + +**Voice test:** Does it sound like a knowledgeable colleague you'd trust with a hard problem? That's the target. + +--- + +## 5. Visual Principles + +1. **Space is intelligence.** Premium brands use breathing room. Only tighten in data-dense product UI. +2. **Data is the design.** Worklist tables and status indicators are primary surfaces — not decoration applied after the fact. +3. **Copper is punctuation on light; warm gold on dark.** One copper accent per section in light mode. On dark teal surfaces, copper-300/400 reads as warm gold — richer expression is permitted. +4. **Typography carries the weight.** A well-set Plus Jakarta Sans 700 headline at the right teal outperforms any icon or illustration. +5. **Never loud, always clear.** No gradients. No glow effects except the deliberate copper-glow shadow token on dark surfaces. No decorative noise. + +--- + +## 6. Master Color Palette + +### Palette Options + +**Option A — PREFERRED DEFAULT: Deep Teal + Refined Copper** +All STTIL Solutions surfaces, Signal CGM UI, pitch decks. +Teal anchors credibility. Copper provides premium restraint in light mode, warm gold sparkle in dark mode. + +**Option B — Navy Teal + Copper** +Cooler, more corporate. Primary `#1A5273`, accent `#C87941`. +Use for investor/board materials. + +**Option C — Forest Teal + Warm Amber (STTIL Journeys seasonal)** +Warmer, earthier. Primary `#1E7A5A`, accent `#C85E2A`. +Stays within parent type and spacing system. + +--- + +### Option A: Teal Scale (Canonical) + +| Token | Hex | Usage | +|-------|-----|-------| +| `teal-50` | `#EEF8F8` | Background washes, hover states | +| `teal-100` | `#CBE9E9` | Bordered containers, soft highlights | +| `teal-200` | `#97D3D3` | Disabled interactive elements | +| `teal-300` | `#5BBBBB` | Secondary text on dark backgrounds | +| `teal-400` | `#2EA3A3` | Icon fills, chart secondary series | +| `teal-500` | `#1A8A8A` | Primary interactive, links | +| `teal-600` | `#147A7A` | **Brand primary — dominant system color** | +| `teal-700` | `#0F5E5E` | Hover state on teal-600 | +| `teal-800` | `#0A4444` | Dark surface foreground, elevated panels | +| `teal-900` | `#072E2E` | Primary dark backgrounds, sidebars, card surfaces | +| `teal-950` | `#041A1A` | Page background in dark mode (AMOLED-deep) | + +### Copper Scale (Dual-Mode: Accent Light / Gold Dark) + +| Token | Hex | Light Mode Usage | Dark Mode Usage | +|-------|-----|-----------------|-----------------| +| `copper-50` | `#FDF3EC` | Copper wash (rare) | — | +| `copper-100` | `#F8DFC5` | Call-out box backgrounds | — | +| `copper-200` | `#F0BC8A` | Illustration accents | Subtle shimmer fills | +| `copper-300` | `#E49655` | Subtle badge fills | **Warm gold text on dark — promoted** | +| `copper-400` | `#D97B35` | Warning/expiry indicators | **Borders, glows, active states on dark** | +| `copper-500` | `#CB6B20` | **Copper accent primary (light)** | CTA fills on dark | +| `copper-600` | `#B05A18` | Copper hover | Hover on dark CTA | +| `copper-700` | `#8C4712` | Text on copper-100 backgrounds | — | +| `copper-800` | `#66330D` | Deep copper (rare) | — | +| `copper-900` | `#3D1E08` | Near-black copper | — | + +**Warm White (dark mode heading tone):** +`warm-white` = `#FFFAF6` — use for primary headings on dark teal surfaces. Slightly copper-tinted vs. pure white; creates warmth at the top of the value hierarchy without appearing beige on a screen. + +### Neutral Scale (Teal-Toned) + +| Token | Hex | Usage | +|-------|-----|-------| +| `neutral-0` | `#FFFFFF` | Card surfaces, pure white | +| `neutral-50` | `#F4F9F9` | Page background (light mode) | +| `neutral-100` | `#E5EEEE` | Dividers, table row alternates | +| `neutral-200` | `#C8D8D8` | Borders, input outlines | +| `neutral-300` | `#A3BEBE` | Placeholder text, disabled | +| `neutral-400` | `#7A9E9E` | Secondary body text | +| `neutral-500` | `#5A7E7E` | Body text minimum on white | +| `neutral-600` | `#426060` | Strong body text | +| `neutral-700` | `#2E4444` | Headings on light | +| `neutral-800` | `#1C2C2C` | Primary text on light | +| `neutral-900` | `#111A1A` | Primary text default | + +### Semantic / Status Colors + +| Token | Hex | Purpose | +|-------|-----|---------| +| `success-500` | `#1A7A4E` | Active coverage, completed | +| `success-100` | `#C8EDD8` | Success background fill | +| `warning-400` | `#D97B35` | Expiring soon (30–59 days) | +| `warning-600` | `#A85A18` | Critical expiry (<30 days) | +| `warning-100` | `#FDECD5` | Warning background fill | +| `error-500` | `#C83030` | Denied, expired, destructive | +| `error-100` | `#F8CCCC` | Error background fill | +| `info-500` | `#1A6A9A` | Informational, pending review | +| `info-100` | `#C8E0EE` | Info background fill | +| `purple-500` | `#7A5EA0` | PA pending, in-process states | +| `purple-100` | `#E2D8F0` | PA pending background fill | + +--- + +## 7. Dark Mode Sparkle Tokens + +These tokens exist specifically for dark-surface (teal-950/teal-900) contexts where copper shifts from accent to warm gold. + +| Token Name | Value | Usage | +|-----------|-------|-------| +| `copper-glow` | `box-shadow: 0 0 16px rgba(217, 123, 53, 0.22)` | Premium card elevation on dark; applied to featured/top-priority cards | +| `copper-border-dark` | `border: 1px solid #D97B35` (copper-400) | Featured card edges on dark surfaces | +| `priority-row-bg` | `background: rgba(203, 107, 32, 0.08)` | Highest-priority row in worklist table; warm gold wash, not orange | +| `active-nav-copper` | `border-left: 3px solid #D97B35` | Active sidebar nav item accent | +| `warm-white` | `#FFFAF6` | Primary heading text on dark teal surfaces | +| `copper-shimmer-border` | `border: 1px solid rgba(228, 150, 85, 0.4)` (copper-300 at 40%) | Subtle shimmer on elevated panels | + +**Dark mode copper rule:** On teal-900/teal-950 backgrounds, copper-300 and copper-400 are permitted for borders, text accents, active states, and priority indicators — because they read as warm gold, not orange. The "one copper per section" restriction applies to light mode only. In dark mode, copper can appear at 2–3 points per section provided it never dominates — teal remains the system color. + +--- + +## 8. Accessibility + +| Pairing | Contrast | Rating | +|---------|----------|--------| +| `teal-900` on `neutral-0` | 15.8:1 | AAA | +| `teal-800` on `neutral-0` | 13.5:1 | AAA | +| `teal-600` on `neutral-0` | 4.8:1 | AA | +| White on `teal-600` | 4.8:1 | AA | +| White on `teal-900` | 15.8:1 | AAA | +| `warm-white` on `teal-950` | 14.2:1 | AAA | +| `copper-300` on `teal-950` | 5.6:1 | AA | +| `copper-400` on `teal-950` | 4.1:1 | AA | +| `copper-500` on `neutral-0` | 3.2:1 | AA large text only | +| `copper-700` on `copper-100` | 5.1:1 | AA | +| `neutral-800` on `neutral-50` | 12.4:1 | AAA | + +**Rules:** +- Copper-500 on white: large text only (18px+ bold or 24px+ regular) +- Copper-300/400 on dark teal: AA-safe for body text and UI labels +- Never use copper as the sole status indicator — pair with icon or label +- Always test new dark surface pairings before shipping + +--- + +## 9. Typography + +| Role | Font | Weights | Source | +|------|------|---------|--------| +| Display / Headings | **Plus Jakarta Sans** | 600, 700 | Google Fonts | +| Body / UI | **Inter** | 400, 500 | Google Fonts | +| Data / Code / IDs | **JetBrains Mono** | 400, 500 | Google Fonts | + +```css +@import url('https://fonts.googleapis.com/css2?family=Plus+Jakarta+Sans:wght@600;700&family=Inter:wght@400;500&family=JetBrains+Mono:wght@400;500&display=swap'); +``` + +**Type Scale:** + +| Token | Size | Weight | Line Height | Usage | +|-------|------|--------|-------------|-------| +| `display-xl` | 3rem / 48px | 700 | 1.15 | Hero headlines | +| `display-lg` | 2.25rem / 36px | 700 | 1.2 | Section headers, slide titles | +| `heading-xl` | 1.875rem / 30px | 700 | 1.25 | Page titles | +| `heading-lg` | 1.5rem / 24px | 600 | 1.3 | Card headers | +| `heading-md` | 1.25rem / 20px | 600 | 1.35 | Sub-section headers | +| `heading-sm` | 1.125rem / 18px | 600 | 1.4 | UI labels, column headers | +| `body-lg` | 1rem / 16px | 400 | 1.6 | Primary body text | +| `body-sm` | 0.875rem / 14px | 400 | 1.5 | Secondary body, form labels | +| `caption` | 0.75rem / 12px | 400 | 1.5 | Metadata, timestamps | +| `data` | 0.875rem / 14px | 500 | 1.4 | JetBrains Mono — numeric values | +| `code` | 0.875rem / 14px | 400 | 1.6 | JetBrains Mono — code/IDs | + +--- + +## 10. Logo Direction Notes + +- **Wordmark:** "STTIL SOLUTIONS" in Plus Jakarta Sans 700, all-caps, letter-spacing +0.05em. Color: `teal-700` on light, `warm-white` on dark. +- **Mark:** Abstract signal waveform or S-form. Precise, not decorative. Single-color only — no gradients. +- **Signal lockup:** "Signal" large (Plus Jakarta Sans 600), "Powered by STTIL Solutions" below in `neutral-400` (light) or `teal-300` (dark). +- No copper in the primary logo — copper is accent, not identity. + +--- + +## 11. How to Use Copper + +### Light Mode — Restraint Rules + +**Use copper for:** +- One CTA per page or screen (secondary button or key action) +- Call-out boxes highlighting a key insight +- PA Required status badge +- One accent per LinkedIn carousel slide +- Warning/expiring range in charts (copper-400) + +**Never use copper for:** +- Page or card backgrounds (copper-100 for a single call-out only) +- Navigation elements +- More than one element per visual section +- Body text on white (fails accessibility at copper-500) +- Large filled blocks — reads as orange at scale + +### Dark Mode — Warm Gold Expression + +On teal-950/teal-900 surfaces, copper behavior shifts: + +**Permitted in dark mode:** +- `copper-400` borders on featured cards (1px) +- `copper-300` text for warm gold label accents +- `copper-glow` box-shadow on priority or featured cards +- `active-nav-copper` left border (3px) on active sidebar item +- `priority-row-bg` (copper-500 at 8% opacity) on top-priority worklist rows +- Up to 2–3 copper touchpoints per section — provided teal remains dominant + +**The copper rule (both modes):** Copper marks what matters most. If everything is accented, nothing is accented. In dark mode, the expanded copper palette creates warmth; in light mode, it creates premium restraint. + +--- + +## 12. Light Mode and Dark Mode + +### Light Mode + +| Surface | Token | Hex | +|---------|-------|-----| +| Page background | `neutral-50` | `#F4F9F9` | +| Card / panel | `neutral-0` | `#FFFFFF` | +| Primary text | `neutral-900` | `#111A1A` | +| Secondary text | `neutral-500` | `#5A7E7E` | +| Border | `neutral-200` | `#C8D8D8` | +| Primary brand | `teal-600` | `#147A7A` | +| Copper accent | `copper-500` | `#CB6B20` | +| Sidebar background | `teal-900` | `#072E2E` | +| Sidebar text | `neutral-0` | `#FFFFFF` | + +### Dark Mode + +| Surface | Token | Hex | +|---------|-------|-----| +| Page background | `teal-950` | `#041A1A` | +| Card / panel | `teal-900` | `#072E2E` | +| Elevated surface | `teal-800` | `#0A4444` | +| Primary heading | `warm-white` | `#FFFAF6` | +| Primary text | `neutral-0` | `#FFFFFF` | +| Secondary text | `teal-300` | `#5BBBBB` | +| Border | `teal-700` | `#0F5E5E` | +| Primary brand | `teal-400` | `#2EA3A3` | +| Copper accent (borders/glows) | `copper-400` | `#D97B35` | +| Copper accent (text/icons) | `copper-300` | `#E49655` | +| Priority row | `priority-row-bg` | `rgba(203,107,32,0.08)` | + +--- + +## 13. Do / Don't + +### Visuals + +| Do | Don't | +|----|-------| +| Tight, well-spaced data tables | Busy dashboards with no hierarchy | +| Plus Jakarta Sans 700 at correct weight | Thin weights or system default fonts | +| Teal-900 sidebar with white nav text | Sidebar gradients or colored nav icons | +| Copper used once per section (light) | Copper as a background or nav color | +| Copper-300/400 as warm gold accents (dark) | Copper dominating over teal in dark mode | +| White cards on neutral-50 page background | Gray cards on white (visual mud) | +| Status badges with icon + label | Color-only status indicators | +| Monochromatic teal range in charts | Rainbow chart palettes | +| `copper-glow` shadow on single priority card | Glow applied to all cards (destroys signal) | + +### Copy + +| Do | Don't | +|----|-------| +| "35–45% first-pass denial rate for CGM claims" | "We're revolutionizing DME billing" | +| "Calculates coverage expiry using CMS wear-day rules" | "AI-powered solution that automates everything" | +| "Built for DMEPOS suppliers managing CGM reorder cycles" | "A tool for anyone in healthcare" | +| Use HCPCS codes and CMS-accurate terminology | Simplify or invent regulatory details | + +### Avoiding Generic AI-Slop Aesthetics + +- No purple gradients — "AI purple" signals commodity, not premium +- No glowing elements except the deliberate `copper-glow` shadow token +- No hero illustrations with floating orbs +- No "futuristic" grid textures or noise overlays +- No blue + purple gradient brand marks +- No "AI" in the product name or tagline — outcomes should speak +- No stock photo doctors smiling at tablets + +--- + +## 14. Application by Surface + +| Surface | Background | Header | CTA | Notes | +|---------|-----------|--------|-----|-------| +| Website | `neutral-50` / white cards | `teal-900` nav, white text | `teal-600` primary, `copper-500` secondary | No gradients | +| Signal UI (dark) | `teal-950` | Plus Jakarta Sans 700, `warm-white` | `teal-600` fill, `copper-400` accent border | Copper-glow on top card | +| LinkedIn carousels | `teal-900` cover, white content slides | Plus Jakarta Sans 700 | `copper-500` on cover | One copper per slide (light slides) | +| Pitch decks | `teal-900` title, `neutral-0` content | White on dark, `teal-700` on light | `copper-100` call-out boxes | Charts: teal-500 primary, copper-400 accent | +| Documentation | `neutral-0` | `teal-700` headers | Copper call-out boxes only | JetBrains Mono for codes/data | + +--- + +## 15. Recommended Next Implementation Steps + +1. Register fonts — Plus Jakarta Sans, Inter, JetBrains Mono via Google Fonts in Signal CGM app and website. +2. Implement design tokens — Apply `design-tokens-v1.json` as CSS custom properties (see `tailwind-theme-v1.md`). +3. Update Tailwind config — Extend theme with full teal/copper/neutral/sparkle scales. +4. Build component baseline — Button, Badge (status variants), Card, Sidebar, WorklistTable. +5. Apply copper-glow to the highest-priority card only per dashboard view — establishes the sparkle hierarchy. +6. Apply brand to pitch deck — teal-900/white split, copper-100 call-out boxes, two-curve workload graph as hero visual. +7. Create LinkedIn carousel template — five slides: hook, problem, data, product, CTA. +8. Audit Signal CGM UI — sweep against color tokens; standardize all status badges. +9. Generate brand assets — mark, wordmark, Signal CGM lockup as locked SVGs. +10. Build Figma/Penpot component library from the tokens. +11. Create one-page partner brand guide PDF for billing company prospects. diff --git a/docs/tailwind-theme-v1.md b/docs/tailwind-theme-v1.md new file mode 100644 index 0000000..a6d75bc --- /dev/null +++ b/docs/tailwind-theme-v1.md @@ -0,0 +1,361 @@ +# STTIL Brand — Tailwind Theme v1 + +**Date:** April 2026 +**Source tokens:** `design-tokens-v1.json` +**Accent family:** Tangerine (replaces copper) + +--- + +## 1. CSS Custom Properties + +Add to your global CSS (e.g., `globals.css`, `base.css`, or `